Statins for Heart Health: Weighing Benefits and Risks, Including Increased Diabetes Risk
While statins like rosuvastatin and atorvastatin effectively lower cholesterol and heart disease risk, they may increase diabetes risk. Learn about the trade-offs and the importance of discussing these with your doctor.
DR T S DIDWA MD
2/27/20244 min read
According to a study published in the journal BMJ, both rosuvastatin and atorvastatin similarly reduced the risk of major heart events in people with coronary artery disease (CAD) over three years. However, rosuvastatin lowered bad cholesterol more but might increase the risk of diabetes and cataract surgery compared to atorvastatin. The choice between these drugs should be made by patients and their doctors, considering individual risk factors and preferences.
Key Findings:
Similar efficacy: Both statins showed comparable effectiveness in reducing the risk of major adverse cardiovascular events (MACE) like death, heart attack, stroke, or revascularization procedures over three years.
Lower LDL cholesterol: Rosuvastatin achieved lower LDL ("bad") cholesterol levels compared to atorvastatin.
Increased risk of diabetes: Rosuvastatin treatment was associated with a higher risk of developing new-onset diabetes requiring medication.
Higher risk of cataract surgery: Individuals in the rosuvastatin group had a slightly higher rate of undergoing cataract surgery.
Other safety measures: No significant differences were observed in other safety aspects, including muscle problems, hospital admissions, or kidney disease.
Study Design:
Type: Randomized, open-label, multicenter trial (participants knew which medication they received)
Location: 12 hospitals in South Korea
Participants: 4400 adults with CAD (age ≥ 19 years)
Intervention: Participants were randomly assigned to receive either rosuvastatin or atorvastatin for three years.
Outcomes:
Primary: Composite of major adverse cardiovascular events (MACE) over three years
Secondary: Safety measures including diabetes, hospitalization, muscle problems, kidney disease, and cataract surgery
In the realm of cardiovascular health, the choice of statin therapy holds paramount importance, particularly for individuals grappling with coronary artery disease (CAD). Statins, renowned for their cholesterol-lowering prowess, play a pivotal role in mitigating the risk of adverse cardiovascular events among this patient cohort. Among the myriad of statins available, rosuvastatin and atorvastatin stand out as the vanguards, offering both high- and moderate-intensity treatment regimens essential for effectively reducing low-density lipoprotein (LDL) cholesterol levels in CAD patients.
The LODESTAR Trial: Unveiling Insights
A seminal endeavour in this landscape is the LODESTAR trial, a randomized study delving into the comparative efficacy and safety profiles of rosuvastatin and atorvastatin over a three-year period in adults grappling with coronary artery disease. The findings of this secondary analysis shed light on critical facets influencing clinical outcomes among CAD patients under these statin regimens.
Key Findings:
Comparable Composite Clinical Outcomes: The study revealed that the risk of a three-year composite of all-cause death, myocardial infarction, stroke, or any coronary revascularization did not exhibit significant variance between the rosuvastatin and atorvastatin cohorts.
LDL Cholesterol Reduction: Notably, rosuvastatin treatment demonstrated superior efficacy in lowering LDL cholesterol levels compared to atorvastatin, with a higher proportion of participants achieving LDL cholesterol levels <1.8 mmol/L throughout the study period.
Incidence of Adverse Events: Despite its cholesterol-lowering prowess, rosuvastatin treatment was associated with a higher incidence of new-onset diabetes mellitus requiring the initiation of antidiabetics and cataract surgery relative to atorvastatin treatment.
SATURN Trial vs. LODESTAR Trial
A point of comparison arises with the SATURN trial, which primarily assessed the effects of high-dose rosuvastatin and atorvastatin on the progression of coronary atherosclerosis via intravascular ultrasonography. While the SATURN trial showcased the superior LDL cholesterol-lowering capacity of rosuvastatin, akin to findings in the LODESTAR trial, the translation of this reduction into clinical benefits remains nuanced.
Pharmacological Discrepancies and Implications
The disparity in LDL cholesterol reduction between rosuvastatin and atorvastatin could be attributed to variances in pharmacological properties, including bonding capacity to HMG-CoA reductase and plasma half-life. Despite rosuvastatin's liver selectivity and pronounced reduction in LDL cholesterol levels, it failed to manifest incremental benefits in clinical outcomes, potentially due to limitations in pleiotropic effects beyond cholesterol lowering.
Safety Considerations: New-Onset Diabetes Mellitus and Cataract Surgery
Safety emerges as a paramount concern in long-term statin therapy, accentuated by the observed increase in new-onset diabetes mellitus associated with rosuvastatin treatment. While the mechanisms underlying this association remain elusive, genetic data suggest a plausible link to the inhibition of HMG-CoA reductase activity. Moreover, the incidence of cataract surgery exhibited variability between statin types, with rosuvastatin showcasing a higher incidence compared to atorvastatin, potentially attributed to its greater LDL cholesterol-lowering capacity.
To Summarize
The LODESTAR trial compares rosuvastatin and atorvastatin in CAD patients over 3 years.
Both statins similarly reduce major heart events; rosuvastatin lowers LDL more.
Rosuvastatin may increase the risk of diabetes and cataract surgery compared to atorvastatin.
The study involved 4,400 CAD patients across 12 hospitals in South Korea.
Primary outcome: composite major adverse cardiovascular events over 3 years.
Rosuvastatin is superior in LDL reduction but associated with a higher diabetes risk.
Safety concerns include increased cataract surgery rates with rosuvastatin.
Reference Article
Lee, Y. J., Hong, S. J., Kang, W. C., Hong, B., Lee, J., Lee, J. B., Cho, H. J., Yoon, J. H., Lee, S., Ahn, C., Kim, J. S., Kim, B., Ko, Y. G., Choi, D., Jang, Y., & Hong, M. K. (2023, October 18). Rosuvastatin versus atorvastatin treatment in adults with coronary artery disease: secondary analysis of the randomised LODESTAR trial. The BMJ. https://doi.org/10.1136/bmj-2023-075837
Related :
Disclaimer
The information on this website is for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition or treatment.Never disregard professional medical advice or delay in seeking it because of something you have read on this website.